Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Asthma is a heterogeneous disorder that is characterized by variable airflow obstruction, airway inflammation and hyperresponsiveness, and reversibility either spontaneously or as a result of treatment. Multiple causes no doubt exist for both its inception and symptom exacerbation once the disease is established. Factors underlying inception can range from viral respiratory tract infections in infancy to occupational exposures in adults. Factors underlying asthma exacerbations include allergen exposure in sensitized individuals, viral infections, exercise, irritants, and ingestion of nonsteroidal anti-inflammatory agents among others. Exacerbating factors might include one or all of these exposures and vary both among and within patients. Asthma treatment is determined to a large extent after an assessment of severity, which can be variable over time and assessed in 2 domains: impairment (current) and risk (long-term consequences). Unfortunately, despite the availability of effective therapies, suboptimal asthma control exists in many patients on a worldwide basis. The future development of novel therapies and treatment paradigms should address these disparities. (J Allergy Clin Immunol 2006;117:S456-61.)

**Key words:** Asthma, respiratory syncytial virus, rhinovirus, allergen, prevention, exacerbation, inception, treatment

**NATURAL HISTORY (INCEPTION AND PROGRESSION)**

For many asthmatic patients, the disease has its roots during infancy and early childhood. Viral respiratory tract infections produce wheezing episodes during the first 3 years of life in about 50% of children. Some of these children will stop wheezing (transient wheezers), whereas others will go on to have persistent symptoms that will either dissipate before adolescence (primarily nonatopic individuals) or continue into adolescence (atopic wheezers). Once in remission, the disease process might remain quiescent or the individual could relapse in later life. The pattern and rate of loss of lung function in asthmatic subjects has been of interest and concern to many investigators. A number of groups have reported that the greatest absolute loss of lung function appears to occur very early in childhood. Some have reported that the peak in lung function that is achieved at about 20 years of age in patients with asthma might be decreased and that the rate of further loss during adulthood might be increased in asthmatic subjects. About one fourth of children with asthma could experience greater rates of loss of lung function, and these children have certain phenotypic characteristics: younger age, male sex, higher postbronchodilator FEV1 percent predicted, and greater airway eosinophilic inflammation. The precise timing for the inception of the inflammatory response characteristic of asthma is unknown. Although recent biopsy studies in wheezing infants who have documented reversible airflow obstruction do not show any consistent inflammatory or structural changes (ie, remodeling), other groups have demonstrated increased numbers of inflammatory cells and mediators in wheezing preschool children. Despite these advances in our understanding of factors contributing to mild persistent asthma in children and their potential for long-term consequences, much still needs to be learned.

**Risk factors**

Risk factors in relationship to asthma have been evaluated in the context of disease inception (eg, viral infections, environmental exposures [eg, aeroallergens, pollution, and tobacco smoke], lifestyle [eg, living on a farm], diet, and antibiotic use), comorbid conditions [eg, atopic dermatitis and obesity], and occupational exposures among others, as well as disease severity (as defined by the risk domain, which is discussed subsequently: hospitalizations, frequency and severity of exacerbations, and loss of lung function). Genetic factors also contribute significantly to disease expression and severity. Asthma is genetically classified

---

32. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004;103:2879-91.

33. Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O’Neill KR, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004;305:1773-6.

34. Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, et al. A critical role for eosinophils in allergic airways remodeling. Science 2004;305:1776-9.
as a complex disorder; as such, it does not follow simple Mendelian inheritance characteristics. Hundreds of genetic association studies on asthma-related phenotypes have been conducted in different populations; these have been recently reviewed. 

Although the importance of gene-by-environment interactions in the expression of disease has recently been highlighted, the complexities involved in analyzing these relationships from a functional perspective have proved to be challenging. Recent pharmacogenetic evaluations in relationship to chronic β-agonist use and corticosteroid efficacy have provided new insights into the variability of response in asthmatic patients.

**Exacerbating factors**

**Allergens.** Allergen exposure is important in host allergic sensitization and as a common precipitant of asthmatic symptoms in both children and adults. The formation of antigen-specific IgE antibody to allergens (eg, mites, trees, grasses, and animal dander) does not usually occur until 2 to 3 years of life. Thus allergen-induced asthma is uncommon during the first year of life but begins to increase in prevalence during later childhood and adolescence and peaks in the second decade of life. Once established in genetically predisposed individuals, IgE-mediated reactions are a major contributor both to acute asthmatic symptoms and chronic airway inflammation. Chronic low-level exposure to indoor allergens (dust mite and cockroach in particular) might play a major role in both asthma inception and subsequent provocation of symptoms. 

Although a wide variety of inhaled allergens can provoke asthma symptoms, sensitization to house dust mite, cockroach, *Alternaria* species, and possibly cat are important in the pathogenesis of asthma. Dog, but not cat, ownership during infancy has been shown to reduce the subsequent development of allergic sensitization and atopic dermatitis; numbers of pets, and not the type of furred pet, might also reduce future risk. These diverse findings indicate that these relationships are indeed complex and might involve gene-by-environment interactions. Pollen immunotherapy in school-aged children with only allergic rhinitis at the start of treatment has been demonstrated to reduce significantly the subsequent risk of the development of airway hyperresponsiveness and asthma.

**Infections.** Respiratory tract infections caused by viruses, *Chlamydia* species, and *Mycoplasma* species have been implicated in the pathogenesis of asthma. Of these respiratory pathogens, viruses have been demonstrated to be epidemiologically associated with asthma in at least 3 ways. First, during infancy, certain viruses have been implicated as potentially being responsible for the inception of the asthmatic phenotype. The virus most convincingly demonstrated in this regard has been respiratory syncytial virus. However, because nearly every child has been infected at least once with this virus by 2 years of age, additional genetic, environmental, or developmental factors must contribute to the propensity of this particular virus to be epidemiologically linked with childhood asthma. Second, in patients with established asthma, particularly children, viral upper respiratory tract infections play a significant role in producing acute exacerbations of airway obstruction that might result in frequent outpatient visits or in hospitalizations. Rhinovirus, the common cold virus, is the most frequent cause of exacerbations, but other viruses, including para-influenza, respiratory syncytial virus, influenza, and coronavirus, also have been implicated, albeit to a lesser extent. The increased tendency for viral infections to produce lower airway symptoms in asthmatic individuals might be related, at least in part, to interactions among allergic sensitization, allergen exposure, and viral infections acting as cofactors in the induction of acute episodes of airflow obstruction. Abnormalities in the innate immune response that would prevent viral replication in airway epithelial cells from asthmatic subjects have recently been demonstrated. Third, paradoxically, infections have been considered to have the potential of actually preventing the development of allergic respiratory tract diseases, including asthma. Interest in this area increased after the advancement of the hygiene hypothesis, which proposed that increasing family size coincident with an increased number of infections might protect against these developments. On the basis of a progressively broader interpretation of this initial hypothesis, a number of other epidemiologic (eg, living on a farm) and biologic (eg, probiotics) factors have been evaluated regarding their ability to influence the development of allergic sensitization, asthma, or both.

For infections with other microbial agents, recent attention has focused on *Chlamydia species* and *Mycoplasma species* as potential contributors to both exacerbations and the severity of chronic asthma in terms of loss of lung function or medication requirements. Finally, infections involving the upper airways (ie, sinusitis) have been considered to contribute to asthma control instability, evoking the concept of a unified airway in relationship to inflammatory responses and alterations in airway physiology.

**Exercise.** Exercise is one of the more common precipitants of airflow obstruction in asthmatic patients. The symptoms of exercise-induced bronchospasm can include any or all of the following: wheezing, coughing, shortness of breath, and, in children, chest pain or discomfort. The symptoms are most intense for 5 to 10 minutes and usually resolve within 15 to 30 minutes after exercise cessation. Under most circumstances, the degree of bronchoconstriction is rarely severe enough to be life-threatening, and such a situation almost invariably reflects advanced untreated disease, confounding triggering factors (ie, concomitant allergen or irritant exposure), or both. Objective documentation of airflow obstruction after an exercise
challenge test (≥15% decrease in FEV₁) or a convincing history with appropriate response to prophylactic or rescue medication is required to make the diagnosis of exercise-induced bronchospasm. Exercise challenge testing must be of sufficient intensity and duration to be able to accurately diagnose the condition, keeping in mind that such confounding problems as vocal cord dysfunction might need to be considered in the differential diagnosis.  

**Nonsteroidal anti-inflammatory drugs.** Approximately 5% to 10% of adult asthmatic patients will have an acute worsening of symptoms to nonsteroidal anti-inflammatory drugs (NSAIDs). The aspirin triad—asthma, nasal polyps, and aspirin sensitivity—is usually found in adult asthmatic patients. The response to aspirin or other NSAIDs begins within an hour of aspirin ingestion and is associated with profound rhinorrhea, eye lacrimation, and, potentially, severe bronchospasm. Patients sensitive to aspirin usually are reactive to all other NSAIDs, and variations in the frequency and severity of adverse responses appear to depend on the potency of each drug within this class of compounds to inhibit the activity of the COX-1 enzyme. The use of COX-2 inhibitors in aspirin-sensitive patients might be possible and worthy of consideration.

The sensitivity to NSAIDs is not IgE mediated but involves the modulation of eicosanoid production. It has been suggested that NSAIDs act by reducing the formation of prostaglandins that help maintain normal airway function while increasing the formation of asthma-provoking eicosanoids, including hydroxyeicosatetraenoic acids and large quantities of cysteinyl leukotrienes. In addition, there is evidence that mast cell activation occurs, and its mediators can be detected in nasal secretions during an episode of aspirin-induced asthma. This syndrome should be of concern in any asthmatic patient with nasal polyposis, chronic sinusitis, and eosinophilia, although the polyposis and sinusitis might precede the onset of recognized NSAID sensitivity by years.

**Gastroesophageal reflux.** The true incidence of gastroesophageal reflux disease (GERD) in asthma and as a causative factor in disease severity has yet to be established. However, it has been estimated that as many as 45% to 65% of adults and children with asthma have GERD. The mechanisms by which GERD affects asthma are also not established but might include microaspiration or irritation of the esophagus with reflux bronchospasm. Although often asymptomatic in its presentation, many patients have nighttime exacerbations or difficult-to-control symptoms. Confirmation of the importance of GERD to asthma often requires endoscopy and 24-hour monitoring of intraesophageal pH levels, with concomitant measures of peak expiratory flow rates. Recognition of this factor in asthma severity is important because effective therapy is currently available.

**Psychosocial factors.** The role of psychosocial factors, or stress, has undergone an important reevaluation both in terms of a disease risk factor and a concomitant component of severity. Evidence has shown that parental stress is a risk factor for asthma expression in some children. The mechanisms by which this occurs have not been defined but might include the promotion of allergic inflammation. Recent work has demonstrated dose-response-type relationships between panic and asthma and bidirectional longitudinal associations between the 2 conditions.

**DISEASE PROGRESSION, PREVENTION, AND TREATMENT**

Although a number of research groups are investigating strategies aimed at asthma prevention, this goal has not yet been achieved. Therefore therapy at present is directed primarily at achieving optimal control while attempting to minimize both short- and long-term side effects from any therapeutic intervention. Asthma control is defined by an understanding of the patient’s asthma severity, which can be viewed in 2 domains: impairment and risk. Impairment is an evaluation of the concurrent degree of control in achieving the following: minimal (or no) chronic symptoms, including nocturnal awakenings caused by asthma; minimal (or no) need for acute rescue therapy, such as inhaled β₂-agonists; establishment of a normal lifestyle with no limitations on activities including exercise; and normalization of pulmonary function. The risk domain includes criteria that deal with future events that the treatment program should either prevent or reduce to the greatest extent possible: reduction (or elimination of) in the frequency and severity of asthma exacerbations; minimal or no loss of lung function over time (considered to be a potential consequence of airway remodeling); and minimal or no adverse effects from medications.

The selection of pharmacologic treatment is determined on the basis of the age of the patient and the severity of his or her asthma. Because asthma is a variable but chronic disease (or syndrome), specific treatment will need to be adjusted both acutely, or during exacerbations, and chronically, in the context of eliminating or reducing both impairment and risk as they dynamically fluctuate over time. A stepwise approach has been adapted for treatment to accomplish these goals (see http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.htm). The basis of the stepwise approach is to increase the number, frequency, and dose of medications with increasing asthma severity until the patient’s disease has been put into remission (ie, achieving optimal control for that individual). Once remission has been established, step-down therapy can be attempted to minimize medication burden whenever possible.

In the last few years, a number of published clinical trials using new therapeutic agents or novel treatment strategies are noteworthy on the basis of their potential effect in initiating or adjusting medication based on this stepwise severity scheme. First, a 1-year-long trial performed by the Asthma Clinical Research Network demonstrated that in very mild persistent asthma (low impairment and low risk), treatment with only a symptom-based action plan (and not daily controller therapy) was sufficient to maintain control of peak flow, asthma...
exacerbations, and quality of life and did not increase loss of lung function during the 1 year of treatment.\(^6\) Although monotherapy with an inhaled corticosteroid in this trial significantly improved prebronchodilator FEV\(_1\), bronchial reactivity, biomarkers of airway inflammation (exhaled nitric oxide and sputum eosinophils), and symptom-free days, the clinical relevance of these changes are open to individual clinician interpretation.

Second, in preschool children with histories consistent with asthma-like symptoms related only to viral infections, treatment with a leukotriene receptor antagonist was shown to significantly reduce both the frequency of these types of exacerbations and the amount of inhaled corticosteroid used to treat these episodes.\(^6\)

Third, 2 studies have evaluated the use of combination products containing an inhaled corticosteroid and a long-acting \(\beta\)-agonist. In the first trial, guideline-defined control was achievable with combination therapy (fluticasone plus salmeterol) in a significant proportion of patients when it was used in escalating doses to reach these outcomes.\(^6\) In the second trial a single inhaler containing a combination product (budesonide plus formoterol) was used both as a daily controller and as a rescue medication. Compared with higher-dose monotherapy with budesonide and a short-acting \(\beta\)-agonist for rescue or the combination product and a short-acting \(\beta\)-agonist for rescue, reductions in the frequency of exacerbations over a 1-year treatment period was significantly greater when the combination therapy was used as both a daily controller therapy and as a rescue medication.\(^6\)

Fourth, therapy guided by physiologic variables or biomarkers, such as airway hyperresponsiveness,\(^6\) sputum eosinophil counts,\(^7\) or exhaled nitric oxide levels,\(^7\) might provide new directions for improving asthma management.

Finally, therapy that globally or more selectively modulates immunoinflammatory networks with the use of anti-IgE mAbs, allergen-derived peptides, modified recombinant allergen vaccines, and immunostimulatory DNA sequences among others\(^2\) offer novel therapeutic strategies both now and in the future.

**SUMMARY**

Asthma is a complex genetic disorder that is characterized by airway inflammation and reversible airflow obstruction. It is further distinguished by multiple phenotypes that might differ on the basis of age of onset, triggering factors, and patterns of severity both during acute exacerbations and on a more chronic basis, as reflected by variably reversible loss of lung function. As a result of this clinical heterogeneity, treatment approaches need to be individualized and modified to obtain and maintain adequate symptom and disease control over time. Although current therapy is targeted at the development of secondary and tertiary prevention strategies, ongoing research is evaluating the prospects of primary prevention as well.

**REFERENCES**

1. Taussig LM, Wright AL, Holtberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson children’s respiratory study: 1980 to present. J Allergy Clin Immunol 2003;111:661-75.
2. Frew AJ. Advances in environmental and occupational disorders. J Allergy Clin Immunol 2003;111(suppl):S824-8.
3. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:40-7.
4. Sears MR, Greene JM, Willan AR, Wicke EM, Taylor DR, Flannery EM, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003;349:1414-22.
5. Phelan PD, Robertson CF, Olinsky A. The Melbourne asthma study: 1964-1999. J Allergy Clin Immunol 2002;109:189-94.
6. Xuan W, Peat JK, Toelle BG, Marks GB, Berry G, Woolcock AJ. Lung function growth and its relation to airway hyperresponsiveness and recent wheeze. Results from a longitudinal population study. Am J Respir Crit Care Med 2000;161:1820-4.
7. Lange P, Parner J, Vestbo J, Schnoor P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339:1194-200.
8. Covar RA, Spahn JD, Murphy JR, Szefler SJ. Progression of asthma measured by lung function in the childhood asthma management program. Am J Respir Crit Care Med 2004;170:234-41.
9. Saglani S, Malmstrom K, Pelkonen AS, Malmberg LP, Lindahl H, Kajosaari M, et al. Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. Am J Respir Crit Care Med 2005;171:722-7.
10. Krawiec ME, Westcott JY, Chu HW, Balzar S, Trudeau JB, Schwartz LB, et al. Persistent wheezing in very young children is associated with lower respiratory inflammation. Am J Respir Crit Care Med 2001;163:1338-43.
11. Bisgaard H, Szefler SJ. Understanding mild persistent asthma in children: the next frontier. J Allergy Clin Immunol 2005;115:708-13.
12. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171:137-41.
13. Salam MT, Li YF, Langholz B, Gilliland FD. Early-life environmental risk factors for asthma: findings from the Children’s Health Study. Environ Health Perspect 2004;112:760-5.
14. Pedersen DB. The epidemiology and genetics of asthma risk associated with air pollution. J Allergy Clin Immunol 2005;115:213-9.
15. Kurukulaaratchy RJ, Matthews S, Arshad SH. Does environment mediate earlier onset of the persistent childhood asthma phenotype? Pediatrics 2004;113:345-50.
16. Morgan WJ, Crain EF, Gruchalla RS, O’Connor GT, Kattan M, Evans R III, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004;351:1068-80.
17. James AL, Palmer LJ, Kicic E, Maxwell PS, Lagan SE, Ryan GF, et al. Decline in lung function in the Busselton health study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005;171:109-14.
18. Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002;347:869-77.
19. Martindale S, McNeill G, Devereux G, Campbell D, Russell G, Seaton A. Antioxidant intake in pregnancy in relation to wheeze and eczema in the first two years of life. Am J Respir Crit Care Med 2005;171:121-8.
20. Mihrshahi S, Peat JK, Mellis CM, Tovey ER, Webb K, et al. Eighteen-month outcomes of house dust mite avoidance and dietary fatty acid modification in the Childhood Asthma Prevention Study (CAPS). J Allergy Clin Immunol 2003;111:162-8.
21. Bjorksten B. Effects of intestinal microflora and the environment on the development of asthma and allergy. Springer Semin Immunopathol 2004;25:257-70.
22. Ili S, Von Mutius E, Lau S, Nickel R, Gruber C, Niggemann B, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004;113:925-31.
23. Guler N, Kiereler E, Ones U, Tamay Z, Salmayenli N, Darendeliler F. Leptin: does it have any role in childhood asthma? J Allergy Clin Immunol 2004;114:254-9.
24. Malo JL, Chan-Yeung M. Occupational asthma. J Allergy Clin Immunol 2001;108:317-28.
25. Belessis Y, Dixon S, Thomsen A, Duffy B, Rawlinson W, Henry R, et al. Risk factors for an intensive care unit admission in children with asthma. Pediatr Pulmonol 2004;37:201-9.
26. Gelb AF, Schein A, Nussbaum E, Shinar CM, Aelony Y, Aharonian H, et al. Risk factors for near-fatal asthma. Chest 2004;126:1138-46.
27. Kraitch BT, Pollock AD, Kantza KM, Dockery DW, Schouten JP, Weiss ST, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004;126:1875-82.
28. Hoffjan S, Nicolae D, Ober C. Association studies for asthma and atopic diseases: a comprehensive review of the literature. Respir Res 2003;4:14-26.
29. Hoffjan S, Nicolae D, Ostrowyna I, Robberg K, Evans M, Mirel DB, et al. Gene-environment interaction effects on the development of immune responses in the 1st year of life. Am J Hum Genet 2005;76:696-704.
30. Eder W, Klimecki W, Yu L, Von Mutius E, Riedler J, Braun-Fahrlander C, et al. Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol 2004;113:482-8.
31. Vercelli D. Genetics, epigenetics, and the environment: switching, buffering, releasing. J Allergy Clin Immunol 2004;113:381-6.
32. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004;364:1505-12.
33. Huff AL, Platts-Mills TAE. Allergens and asthma. Pediatr Clin North Am 1992;39:1277-91.
34. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 1990;323:502-7.
35. Rosenstreich DL, Eggleston P, Kattan M, Baker D, Slavin RG, Gergen P, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 1997;336:1356-63.
36. Bush RK, Prochau J. Alternaria-induced asthma. J Allergy Clin Immunol 2004;113:227-34.
37. Platts-Mills TA, Vaughan JW, Blumenthal E, Pollock SS, Sporik RB. Serum IgG and IgG4 antibodies to Fel d 1 among children exposed to 20 microg Fel d 1 at home: relevance of a nonallergic modified Th2 response. Int Arch Allergy Immunol 2001;124:126-9.
38. Gern JE, Reardon CL, Hoffjan S, Nicolae D, Li Z, Robberg KA, et al. Effects of dog ownership and genotype on immune development and atopy in infancy. J Allergy Clin Immunol 2004;113:307-14.
39. Owby DR, Johnson CC, Peterson EL. Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age. JAMA 2002;288:963-72.
40. Moller C, Dreborg S, Fodero HA, Halken S, Host A, Jacobson L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-6.
41. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005;201:937-47.
42. Webley WC, Salva PSA, Andrzezewski C, Cirino F, West CA, Tilahun Y, et al. The bronchial lavage of pediatric patients with asthma contains infectious Chlamydia. Am J Respir Crit Care Med 2005;171:1083-8.
43. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002;121:1782-8.
44. Lemanske RF Jr. Viral infections and asthma inception. J Allergy Clin Immunol 2004;114:1023-6.
45. Johnston NW, Johnston SL, Duncan JM, Greene JM, Kebadze T, Keith PK, et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol 2005;115:132-8.
46. Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: a case-control study. BMJ 2002;324:763-8.
47. Rakes GP, Arruda E, Ingram JM, Hoover GE, Zambrano JC, Hayden FG, et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med 1999;159:785-90.
48. Strachan DP. Family size, infection and atopy: the first decade of the “hygiene hypothesis.”. Thorax 2000;55(suppl 1):S2-10.
49. Liu AH, Szeffler SJ. Advances in childhood asthma: hygiene hypothesis, natural history, and management. J Allergy Clin Immunol 2003;111(suppl);S785-92.
50. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isoaari E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-9.
51. Simons FEI. Allergic rhinoconjunctivitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999;104:534-40.
52. Storms WW. Asthma associated with exercise. Immunol Allergy Clin North Am 2005;25:31-43.
53. Randell KW, Judelson DA, Williams S. Diagnosis of exercise-induced asthma in the elite athlete. In: Randell KW, Wilber RL, Lemanske RF Jr, editors. Exercise-induced asthma. Pathophysiology and treatment. Champaign (IL): Human Kinetics Publishers, Inc; 2002. p. 181-210.
54. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003;111:913-21.
55. Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Rubin P, Cohn J, et al. Direct evidence for role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994;94:1046-56.
56. Harding SM. Gastroesophageal reflux and asthma: insight into the association. J Allergy Clin Immunol 1999;104:251-9.
57. Wright RJ, Cohen S, Carey V, Weiss ST, Gold DR. Parental stress as a predictor of wheezing in infancy: a prospective birth-cohort study. Am J Respir Crit Care Med 2002;165:358-65.
58. Hasler G, Gergen PK, Kleinbaum DG, Ajlaccvic V, Gamma A, Eich D, et al. Asthma and panic in young adults: a 20-year prospective community study. Am J Respir Crit Care Med 2005;171:1224-30.
59. Schonberger HJ, Dompeling E, Knottnerus JA, Maas T, Muris JW, van Weel C, et al. The PREVASC study: the clinical effect of a multifaceted educational intervention to prevent childhood asthma. Eur Respir J 2005;25:660-70.
60. Becker A, Watson W, Ferguson A, Dimich-Ward H, Chan-Yeung M. The Canadian asthma primary prevention study: outcomes at 2 years of age. J Allergy Clin Immunol 2004;113:650-6.
61. Guilbert TW, Morgan WJ, Krawiec M, Lemanske RF Jr, Sonksen C, Szeffler SJ, et al. The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education network. Control Clin Trials 2004;25:286-310.
62. Arshad SH, Bateman B, Matthews SM. Primary prevention of asthma and atopy during childhood by allergen avoidance in infancy: a randomised controlled study. Thorax 2003;58:489-93.
63. Gore C, Custovic A. Preventive measures and their effects. Results from cohort studies. Padiatr Respir Rev 2002;3:205-18.
64. National Asthma Education and Prevention Program. Expert Panel Report: guidelines for the diagnosis and management of asthma update on selected topics—2002. J Allergy Clin Immunol 2002;110(suppl):S141-219.
65. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352:1519-28.
66. Bisgaard H, Zelen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005;171:315-22.
67. Bateman ED, Boushey HA, Boussauet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved?: The gain-losing optimal asthma control study. Am J Respir Crit Care Med 2004;170:836-44.
68. O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36.
69. Sont JK, Willems LN, Bel EH, Van Krieken JH, Vandenburgoucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159:1043-51.
7. Control of allergic airway inflammation through immunomodulation

Among the asthma clinical trials published over the last several years, a unique subset has focused on novel means for inhibiting the airway inflammation that is believed to cause airway obstruction in many patients. Such interventions, broadly considered here as immune-modifying or immunomodulatory therapies, include several new drugs (omalizumab, suplatast tosilate, anti-cytokine antibodies, soluble receptors, and recombinant cytokines) and bacterial extracts. In this chapter we review the major findings with these clinical trials and indicate which have changed the management of asthma, which have not, and those that deserve further study. (J Allergy Clin Immunol 2006;117:S461-4.)

Key words: Asthma, IgE, type I hypersensitivity, immunomodulation, T_{H}2 cell, eosinophil, mast cell, interleukin, airway hyperreactivity, immunostimulatory sequence

Allergic asthma is an increasingly common ailment, affecting at least 10% of adults in industrialized countries at some point in their lives. Consequently, research into the causes of asthma and attempts to improve therapies have increased substantially over the last decade. Increasingly, asthma clinical trials have focused on specific immune molecules and signaling pathways that regulate airway disease in asthma. Other interventions, although not directed at any specific inflammatory pathway, nonetheless inhibit allergic inflammation through novel means. Shared among these diverse studies is the recognition of the central role that inflammation, especially type I hypersensitivity mechanisms, play in asthma and the need to inhibit them (Fig 1). In this chapter we review results from recent studies that have used various immunomodulatory approaches to inhibit allergic inflammation in asthma.

Many clinical trials are based on extensive analysis of particular agents in animal models, and where relevant, results from animal studies are briefly discussed. Although more established agents, such as glucocorticosteroids and leukotriene receptor antagonists, are also immunomodulatory, their use is considered separately in another chapter of this Primer. Many of the topics considered here were developed recently, and most of the available literature will be reviewed. However, other topics, such as abatement of sinusitis and allergen reduction, are very large, and only the most recent studies showing immunomodulatory-like effects in asthma will be considered.

RECENT CLINICAL TRIALS EXAMINING IMMUNOMODULATION IN ASTHMA

Manipulation of immunoglobulins

Omalizumab represents the first new class of anti-asthma therapeutics approved by the US Food and Drug Administration in more than 8 years, a humanized anti-IgE mAb. This novel drug binds to the Fc portion of IgE, preventing its association with immunoglobulin crystallizable fraction ~. receptor 1 and therefore binding to mast cells. By thus “disarming” mast cells, omalizumab is intended to interrupt type I hypersensitivity reactions and lessen asthma attacks. Omalizumab reduces serum IgE levels by at least 95%,1 reduces sputum eosinophilia by 90%, and, within the lung, significantly decreases the number of inflammatory cells expressing CD4, IL-4, immunoglobulin crystallizable fraction ~ receptor 1, and CD20.2 Early studies with omalizumab involved small numbers of patients and indicated that it suppressed early- and late-phase responses to inhaled allergen. Larger studies then showed that symptoms of adult patients were improved on the medication, and patients were able to

From the Departments of Medicine and Immunology, Baylor College of Medicine, Houston.
Supported by National Institutes of Health grants HL69585 and HL75243 (to D.B.C.) and HL64061 and HL72062 (to F.K.).
Reprint requests: David B. Corry, MD, Baylor College of Medicine, Medicine/Pulmonary Section, One Baylor Plaza, Suite 520B, Houston, TX, 77030. E-mail: dcorry@bcm.tmc.edu.
0901-6749/$32.00
© 2006 American Academy of Allergy, Asthma and Immunology
doi:10.1016/j.jaci.2005.09.001

Abbreviation used
sIL-4R~: Soluble IL-4 receptor ~

70. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
71. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73.
72. Casale TB. Status of immunotherapy: current and future. J Allergy Clin Immunol 2004;113:1036-9.
73. Norman PS. Immunotherapy: 1999-2004. J Allergy Clin Immunol 2004;113:1013-23.
74. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004;113:1025-34.
75. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115:459-65.